Ciclesonide

Catalog No.S4646 Batch:S464603

Technical Data

Formula	C₃₂H₄₄O₇
Molecular Weight	540.69	CAS No.	126544-47-6
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (184.94 mM)
		Water	Insoluble

* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Ciclesonide (Alvesco, Omnaris, RPR251526, Zetonna) is a glucocorticoid used to treat obstructive airway diseases.
In vitro	Ciclesonide is effectively taken up into human alveolar type II epithelial (A549) cells and metabolized to its pharmacologically active metabolite des-CIC and fatty acid conjugates of desCIC^[2].

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Human alveolar type II epithelial cells (A549). Concentrations 0.02 μM Incubation Time 1 h Method Metabolism of ciclesonide: After initial cultivation, A549 cells are washed five times with 10 ml/dish sterile PBS. An ethanolic stock solution of ciclesonide is diluted 1000-fold with assay medium to generate the initial ciclesonide concentration. The cells are incubated for 1 h in DMEM/0.1% (w/v) BSA (5 ml/dish) containing 0.02μM ciclesonide as described above in a CO2 incubator. At the end of the incubation period, dishes are washed five times with PBS and incubated for 3, 6, or 24 h at the same conditions in 5 ml/dish fresh medium (DMEM/0.1% (w/v) BSA). At each indicated time point, the medium is removed by aspiration, 5 mM EDTA-4Na/PBS added and dishes are incubated for further 5 min. The cells are detached from the dishes and harvested. Each dish is washed five times with icechilled PBS.
Animal Study:^{^[1]}	Animal Models Wistar rats Dosages 0.5 mg/kg Administration i.v.

Cell Assay:^{^[2]}

Cell lines
Human alveolar type II epithelial cells (A549).
Concentrations
0.02 μM
Incubation Time
1 h
Method
Metabolism of ciclesonide: After initial cultivation, A549 cells are washed five times with 10 ml/dish sterile PBS. An ethanolic stock solution of ciclesonide is diluted 1000-fold with assay medium to generate the initial ciclesonide concentration. The cells are incubated for 1 h in DMEM/0.1% (w/v) BSA (5 ml/dish) containing 0.02μM ciclesonide as described above in a CO2 incubator. At the end of the incubation period, dishes are washed five times with PBS and incubated for 3, 6, or 24 h at the same conditions in 5 ml/dish fresh medium (DMEM/0.1% (w/v) BSA). At each indicated time point, the medium is removed by aspiration, 5 mM EDTA-4Na/PBS added and dishes are incubated for further 5 min. The cells are detached from the dishes and harvested. Each dish is washed five times with icechilled PBS.

Animal Study:^{^[1]}

Animal Models
Wistar rats
Dosages
0.5 mg/kg
Administration
i.v.

References

Selleck's Ciclesonide has been cited by 6 publications

Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease [ Acta Pharm Sin B, 2023, 13(2):662-677]	PubMed: 36873178
The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide [ Am J Physiol Lung Cell Mol Physiol, 2023, 324(5):L722-L736]	PubMed: 36976925
Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model [ mBio, 2022, 13(1):e0304421]	PubMed: 35100870
The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b [ Pharmaceutics, 2022, 14(7)1511]	PubMed: 35890406
Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients [ J Cell Biochem, 2022, 10.1002/jcb.30213]	PubMed: 35037717
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction [ Drug Test Anal, 2020, 10.1002/dta.2917]	PubMed: 32852861

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.